The apoptotic and autophagic properties of two natural occurring prodrugs, hyperoside and hypoxoside, against pancreatic cancer cell lines

Biomedicine and Pharmacotherapy

Volumn 83, Issue , 2016, Pages 617-626

  Boukes, Gerhardt J ^a   van de Venter, Maryna ^a  

^a NELSON MANDELA METROPOLITAN UNIVERSITY   (South Africa)

Author keywords

Apoptosis; Autophagy; Hyperoside; Hypoxoside; INS 1; MIA PaCa 2

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; HARPAGOSIDE; HYPERIN; HYPOXOSIDE; MELPHALAN; OLEUROPEIN; PICEID; QUERCETIN; UNCLASSIFIED DRUG; ACRIDINE ORANGE; ALKYNE; DNA; GLUCOSIDE; MICROTUBULE ASSOCIATED PROTEIN; PRODRUG; TUMOR MARKER;

A549 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HELA CELL LINE; HT 29 CELL LINE; HUMAN; HUMAN CELL; IC50; INS 1 CELL LINE; MCF 7 CELL LINE; MIA PACA 2 CELL LINE; NONHUMAN; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANALOGS AND DERIVATIVES; ANIMAL; AUTOPHAGOSOME; CELL CYCLE CHECKPOINT; CELL NUCLEUS; CHEMISTRY; DRUG EFFECTS; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; STAINING; TUMOR CELL LINE;

ACRIDINE ORANGE; ALKYNES; ANIMALS; APOPTOSIS; AUTOPHAGOSOMES; AUTOPHAGY; BIOMARKERS, TUMOR; CASPASE 3; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL NUCLEUS; DNA; ENZYME ACTIVATION; GLUCOSIDES; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; PANCREATIC NEOPLASMS; PRODRUGS; QUERCETIN; RATS; STAINING AND LABELING;

EID: 84989859271     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.07.029     Document Type: Article

References (42)

1. [1] Herbst, M.C., Fact Sheet on Pancreatic Cancer. 2015, Cancer Association of South Africa (CANSA), 1–20.
2. [2] Heinemann, V., Gemcitabine: progress in treatment of pancreatic cancer. Oncology 60 (2001), 8–18.
3. [3] Hidalgo, M., Cascinu, S., Kleeff, J., Labianca, R., Löhr, J.M., Neoptolemos, J., Real, F.X., Van Laethem, J., Heinemann, V., Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology 15 (2015), 8–18.
4. [4] Pai, M., Spalding, D., Pancreatic cancer. Medicine, 2015, 10.1016/j.mped.2015.03.001.
5. [5] Xie, D., Xie, K., Pancreatic cancer stromal biology and therapy. Genes Dis., 2015, 10.1016/j.gendis.201501.002.
6. [6] Nakamura, T., Masuda, K., Harada, S., Akioka, K., Sako, H., Pancreatic cancer: slow progression in the early stages. Int. J. Surg. Case Rep. 4 (2013), 693–696.
7. [7] Smith, B.D., Smith, G.L., Hurria, A., Hortobagyi, G.N., Buchholz, T.A., Future of cancer incidence in the United States: burdens upon an aging changing nation. J. Clin. Oncol. 27 (2009), 2758–2765.
8. [8] Tranoy-Opalinsky, I., Legigan, T., Barat, R., Clarhaut, J., Thomas, M., Renoux, B., Papot, S., β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update. Eur. J. Med. Chem. 74 (2014), 302–313.
9. [9] Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., Savolainen, J., Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7 (2008), 255–270.
10. [10] Yang, Y., Aloysius, H., Inoyama, D., Chen, Y., Hu, L., Enzyme-mediated hydrolytic activation of prodrugs. Acta Pharm. Sin. B 1 (2011), 143–159.
11. [11] Gilliam, A.D., Watson, S.A., Emerging biological therapies for pancreatic carcinoma. Eur. J. Surg. Oncol. 28 (2002), 370–378.
12. [12] Kruger, P.B., Albrecht, C.F., Van Jaarsveld, P.P., Use of guanidine hydrochloride and ammonium sulfate in comprehensive in-line sorption enrichment of xenobiotics in biological fluids by high performance liquid chromatography. J. Chromatogr. 612 (1993), 191–198.
13. [13] Kruger, P.B., Albrecht, C.F., Liebenberg, R.W., Van Jaarsveld, P.P., Studies on hypoxoside and rooperol analogues from Hypoxis rooperi and Hypoxis latifolia and their biotransformation in man by using high-performance liquid chromatography with in-line sorption enrichment and diode-array detection. J. Chromatogr. 662 (1994), 71–78.
14. [14] Holst-Hansen, C., Brünnner, N., MTT-cell proliferation assay. Celis, J.E., (eds.) Cell Biology: A Laboratory Handbook, 2nd ed., 1998, Academic Press, San Diego, 16–18.
15. [15] Asfari, M., Janjic, D., Meda, P., Li, G., Halban, P.A., Wollheim, C.B., Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 130 (1992), 167–178.
16. [16] Mouria, M., Gukovskaya, A.S., Jung, Y., Buechler, P., Hines, O.J., Reber, H.A., Pandol, S.J., Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial c release and apoptosis. Int. J. Cancer 98 (2002), 764–769.
17. [17] Zhang, L., Feng, L., Jia, Q., Xu, J., Wang, R., Wang, Z., Wu, Y., Li, Y., Effect of β-glucosidase hydrolyzed prodructs of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro. Bioorgan. Med. Chem. 19 (2011), 4882–4886.
18. [18] Yang, J., Qian, D., Guo, J., Jiang, S., Shang, E., Duan, J., Xu, J., Identification of the major metabolites of hyperoside produced by the human intestinal bacteria using the ultra performance liquid chromatography/quadrupole-time-of-flight mass spectrometry. J. Ethnopharmacol. 147 (2013), 174–179.
19. [19] Guo, J., Xue, C., Shang, E., Duan, J., Tang, Y., Qian, D., Identification of hyperoside metabolites in rat using ultra performance liquid chromatography/quadropole-time-of-flight mass spectrometry. J. Chromatogr. B 879 (2011), 1987–1992.
20. [20] Smit, B.J., Albrecht, C.F., Liebenberg, R.W., Kruger, P.B., Freestone, M., Gouws, L., Theron, E., Bouic, P.J.D., Etsebeth, S., van Jaarsveld, P.P., A phase I trial of hypoxoside as an oral prodrug for cancer therapy—absence of toxicity. S. Afr. Med. J. 9 (1995), 865–870.
21. [21] Carrera-González, M.P., Ramírez-Expósito, M.J., Mayas, M.D., Martínez-Martos, J.M., Protective role of oleuropein and its metabolite hydroxytyrosol on cancer. Trends Food Sci. Technol. 31 (2013), 92–99.
22. [22] Storniolo, C.E., Moreno, J.J., Resveratrol metabolites have an antiproliferative effect on intestinal epithelial cancer cells. Food Chem. 134 (2012), 1385–1391.
23. [23] Albrecht, C.F., Theron, E.J., Kruger, P.B., Morphological characterization of the cell-growth inhibitory activity of rooperol and pharmacokinetic aspects of hypoxoside as an oral prodrug for cancer therapy. S. Afr. Med. J. 85 (1995), 853–860.
24. [24] Boukes, G.J., Daniels, B.B., Albrecht, C.F., van de Venter, M., Cell survival or apoptosis: rooperol's role as anticancer agent. Oncol. Res. 18 (2010), 365–376.
25. [25] Theron, E.J., Albrecht, C.F., Kruger, P.B., Jenkins, K., van der Merwe, M.J., β-Glucosidase activity in fetal bovine serum renders the plant glucoside, hypoxoside, cytotoxic toward B16-F10-BL-6 mouse melanoma cells. In Vitro Cell. Dev. Biol. Anim. 30A (1994), 115–119.
26. [26] Li, Y., Wang, Y., Li, L., Kong, R., Pan, S., Ji, L., Liu, H., Chen, H., Sun, B., Hyperoside induces apoptosis and inhibits growth in pancreatic cancer via Bcl-2 family and NF-κB signaling pathway both in vitro and in vivo. Tumor Biol., 2015, 10.1007/s13277-015-4552-2.
27. [27] Zhang, N., Ying, M., Wu, Y., Zhou, Z., Ye, Z., Li, H., Lin, D., Hyperoside, a flavonoid compound, inhibits proliferation and stimulates osteogenic differentiation of human osteosarcoma cells. PLoS One, 2014, 10.1371/journal.pone.0098973.
28. [28] Angst, E., Park, J.L., Moro, A., Lu, Q., Lu, X., Li, G., King, J., Chen, M., The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. Pancreas 41 (2013), 223–229.
29. [29] Olayinka, E.T., Ore, A., Ola, O.S., Adeyemo, O.A., Protective effect of quercetin on melphalan-induced oxidative stress and impaired renal and hepatic functions in rat. Chemother. Res. Pract., 2014, 10.1155/2014/936526.
30. [30] Ziegler, U., Groscurth, P., Morphological features of cell death. News Physiol. Sci. 19 (2004), 124–128.
31. [31] Fu, T., Wang, L., Jin, X., Sui, H., Liu, Z., Jin, Y., Hyperoside induces both autophagy and apoptosis in non-small cell lung cancer cells in vitro. Acta Pharmacol. Sin. 37 (2016), 505–518.
32. [32] Guon, T.A., Chung, H.S., Hyperoside and rutin of Nelumbo nucifera induce mitochondrial apoptosis through a caspase-dependent mechanism in HT-29 human colon cancer cells. Oncol. Lett. 11 (2016), 2463–2470.
33. [33] Li, W., Liu, M., Xu, Y., Feng, Y., Che, J., Wang, G., Zheng, J., Combination of quercetin and hyperoside has anticancer effects on renal cancer cells through inhibition of oncogenic microRNA-27a. Oncol. Rep. 31 (2014), 118–124.
34. [34] Jung, S.K., Lim, T.G., Kim, J.E., Byun, S., Kim, G., Choi, J.N., Lee, C.H., Kim, B.Y., Lee, K.W., Lee, H.J., Inhibitory effect of ERK1/2 and AP-1 by hyperoside isolated from Acanthopanax sessiliflorus. Food Chem. 13 (2012), 915–920.
35. [35] Mukubou, H., Tsujimura, T., Sasaki, R., Ku, Y., The role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiation. Int. J. Oncol. 37 (2010), 821–828.
36. [36] Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J.M., Dell'Antonio, G., Mautner, J., Tonon, G., Haigis, M., Shirihai, O.S., Doglioni, C., Bardeesy, N., Kimmelman, A.C., Pancreatic cancers require autophagy for tumor growth. Genes Dev. 25 (2011), 717–729.
37. [37] Hansen, T.E., Johansen, T., Following autophagy step by step. BMC Biol., 2011, 10.1186/1741-7007-9-39.
38. [38] Mizushima, N., Autophagy: process and function. Genes Dev. 21 (2007), 2861–2873.
39. [39] Geng, Y., Kohli, L., Klocke, B.J., Roth, K.A., Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent. Neuro-Oncology 12 (2000), 473–481.
40. [40] Fang, B., Xiao, H., Rapamycin alleviates cisplatin-induced ototoxicity in vivo. Biochem. Biophys. Res. Commun. 448 (2014), 443–447.
41. [41] Kim, S.E., Park, H.J., Jeong, H.K., Kim, M.J., Kim, M., Bae, O.N., Baek, S.H., Autophagy sustains the survival of human pancreatic cancer PANC-1 cells under extreme nutrient deprivation conditions. Biochem. Biophys. Res. Commun. 463 (2015), 205–210.
42. [42] Ni, H., Bockus, A., Wozniak, A.L., Jones, K., Weinman, S., Yin, X., Ding, W., Dissecting the dynamic turnover of GFP-LC3 in the autolysosomes. Autophagy 7 (2011), 188–204.